FDA approves GW’s cannabinoid drug Epidiolex
GW Pharmaceuticals’ Epidiolex has become the first cannabinoid prescription medicine to be approved in the US, winning clearance to treat two rare forms of epilepsy.
Read More
Tag: GW
GW’s Epidiolex takes a leap toward US approval
Shares in GW Pharma were given a boost after its cannabinoid Epidiolex took a giant leap towards US approval for treating seizures linked with Lennox-Gastaut (LGS) and Dravet syndromes.
Read More
GW’s cannabinoid fails in focal seizures trial
A mid-stage trial assessing an experimental cannabinoid being developed by GW Pharma for adults with focal seizures has failed to hit key targets.
Read More
Lancet-published data show potential of GW’s Epidiolex
The Lancet has published data from a Phase III study backing use of GW Pharmaceutical/Greenwich Bioscience’s Epidiolex in patients with Lennox-Gastaut syndrome (LGS).
Read More
GW’s cannabinoid Epidiolex under EU, US review
Regulators on both sides of the Atlantic are now reviewing GW Pharmaceuticals’ cannabinoid Epidiolex as a potential treatment for seizures associated with Lennox-Gastaut syndrome (LGS) or Dravet syndrome.
Read More
GW regains US rights to Sativex
GW Pharmaceuticals has reacquired full ownership of US rights to its cannabinoid medicine Sativex following the termination of a previous license agreement with Otsuka.
Read More
GW completes Epidiolex submission
GW Pharmaceuticals and its US subsidiary Greenwich Biosciences have completed the rolling submission of Epidiolex as adjunctive treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome, two difficult-to-treat forms of childhood-onset epilepsy.
Read More
GW planing to test its cannabinoids in cancer
GW Pharma is strengthening its focus on oncology after promising mid-stage data for its cannabis-based therapy in patients with a rare and aggressive brain tumour called glioblastoma multiforme (GBM).
Read More
GW prepares for acquisition approaches
GW Pharmaceuticals is reportedly preparing itself for takeover approaches as its attractiveness continues to grow with the increasing potential of its cannabinoid portfolio.
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
